Study 2 of 3Petrelintide literatureThe lancet. Diabetes & endocrinologyTop journal2026
Petrelintide and the evolving role of amylin agonism in obesity.
Not reported in abstract.
Where it sits
this study against the rest of the petrelintide corpus1
Preclinical · this one
0
Observational
1
Open-label
1
Randomised
0
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2026
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.
Elsewhere in the Petrelintide corpus
BInitial HIV Therapy for Adults and Treatment-Associated Weight Gain: The Opti-DOR Randomized Clinical Trial.JAMA · 2026HumanAPetrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial.The lancet. Diabetes & endocrinology · 2026 · -9.8% bodyweight change at 28 weeks with petrelintide 5.0 mg vs -1.7% with placebo.Human